Authors
Nicholas A Kennedy, Gareth-Rhys Jones, Christopher A Lamb, Richard Appleby, Ian Arnott, R Mark Beattie, Stuart Bloom, Alenka J Brooks, Rachel Cooney, Robin J Dart, Cathryn Edwards, Aileen Fraser, Daniel R Gaya, Subrata Ghosh, Kay Greveson, Richard Hansen, Ailsa Hart, A Barney Hawthorne, Bu'Hussain Hayee, Jimmy K Limdi, Charles D Murray, Gareth C Parkes, Miles Parkes, Kamal Patel, Richard C Pollok, Nick Powell, Chris S Probert, Tim Raine, Shaji Sebastian, Christian Selinger, Philip J Smith, Catherine Stansfield, Lisa Younge, James O Lindsay, Peter M Irving, Charlie W Lees
Publication date
2020/6/1
Journal
Gut
Volume
69
Issue
6
Pages
984-990
Publisher
BMJ Publishing Group
Description
The COVID-19 pandemic is putting unprecedented pressures on healthcare systems globally. Early insights have been made possible by rapid sharing of data from China and Italy. In the UK, we have rapidly mobilised inflammatory bowel disease (IBD) centres in order that preparations can be made to protect our patients and the clinical services they rely on. This is a novel coronavirus; much is unknown as to how it will affect people with IBD. We also lack information about the impact of different immunosuppressive medications. To address this uncertainty, the British Society of Gastroenterology (BSG) COVID-19 IBD Working Group has used the best available data and expert opinion to generate a risk grid that groups patients into highest, moderate and lowest risk categories. This grid allows patients to be instructed to follow the UK government’s advice for shielding, stringent and standard advice regarding social …
Scholar articles
NA Kennedy, GR Jones, CA Lamb, R Appleby, I Arnott… - Gut, 2020